Consure Medical is a technology company.
Consure Medical has raised $470K across 1 funding round.
Consure Medical has raised $470K in total across 1 funding round.
Consure Medical has raised $470K in total across 1 funding round.
Consure Medical's investors include Good Startup, Venture Catalysts | India's First Integrated Incubator.
Consure Medical is a medical device company developing and commercializing innovative technologies for critical care, primarily targeting fecal and urinary incontinence management in acute, sub-acute, and chronic settings.[1][2][3] Its products serve ICU patients and nurses, solving problems like hospital-acquired infections (e.g., CAUTI), nursing burden, and high care costs—impacting 100 million patients annually at over $10 billion in expenses—by automating irrigation, milking, and providing intelligent indicators for efficient care.[2][3][7] With six commercial products used in about 600 U.S. ICUs, regulatory clearance in seven countries, and strong growth in the U.S. (90-95% of business), the company demonstrates solid momentum, including clinical studies showing 75% infection reductions, shorter hospital stays, and up to 174 minutes daily nursing time savings.[3]
Founded in 2012 by Nish Chasmawala and Amit Sharma, Consure Medical originated from a mission to address incontinence challenges in emerging markets like India but pivoted to the U.S. amid the Affordable Care Act's penalties on hospital-acquired infections, which aligned perfectly with their solutions.[2][3][6] Chasmawala, with a background in biodesign (noted in Stanford affiliations), and Sharma developed the idea through collaboration with nurses, evolving from traditional ideation to first-generation products that leapfrogged pads and catheters, proving highly effective in reducing infections and costs ($25,000–$300,000 per hospital annually).[3][6] Early traction came from clinical studies validating outcomes, leading to commercialization across six products now in widespread ICU use.[3]
Consure Medical rides the aging population wave—U.S. 65+ projected at 80 million by 2050—increasing fecal incontinence and digestive needs, amid a bowel management market growing to $3.72 billion by 2034 at 2.38% CAGR, fueled by R&D in smart tech, materials, and user-friendly designs.[2] Timing leverages U.S. policies like the Affordable Care Act penalizing infections, plus North American innovation investments, positioning it against pads/balloons in a sector demanding efficiency amid nursing shortages.[3] It influences medtech by humanizing critical care, reducing $10B+ incontinence costs, and setting benchmarks for infection prevention in ICUs, potentially expanding to home care and global emerging markets.[2][3][7]
With U.S. dominance and international clearances, Consure Medical is poised for accelerated growth via 2024+ geographic expansion, deeper ICU penetration, and pipeline leveraging three patents amid rising elderly care demands.[2][3][5] Trends like smart incontinence tech, AI-driven monitoring, and cost pressures from aging demographics will propel it, potentially evolving influence through home/ambulatory adaptations and broader GI platforms. This critical care innovator, born from nurse needs, stands to transform incontinence management at scale.
Consure Medical has raised $470K across 1 funding round. Most recently, it raised $470K Series B in April 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2020 | $470K Series B | Good Startup, Venture Catalysts | India's First Integrated Incubator |